Neuromonics Announces Recruitment for December Product Trial of Downloadable Tinnitus Solution
WESTMINSTER, Colo. (PRWEB) November 18, 2015 -- Neuromonics, Inc., maker and distributor of patented and clinically proven medical devices designed for significant relief of tinnitus, is launching a product trial of a downloadable tinnitus treatment for mobile devices.
The trial, which is recruiting consumers, will take place in December. Results and feedback from the trial will help Neuromonics refine the mobile solution before its planned market launch in early 2016.
The trial will provide a downloadable version of the Neuromonics Oasis™ to participating tinnitus sufferers through any iOS-enabled device. Long considered the “gold standard” in tinnitus treatment, the Oasis uses a proven, effective treatment protocol delivered through an easy-to-use compact device.
Neuromonics will accept the first 250 qualifying applicants. Individuals who suffer from tinnitus, own an iOS mobile device, and want more information on participation in the trial, can contact Neuromonics at 866-606-3876 or trial(at)neuromonics(dot)com, or complete an online application.
“This is an excellent opportunity for consumers to realize the benefit of Neuromonics’ proven treatment without the cost typically involved,” says Eula Adams, CEO of Neuromonics. “At the same time, Neuromonics will obtain valuable information to improve and perfect the downloadable product for its market release.”
According to the American Tinnitus Association, more than 50 million people in the United States suffer from tinnitus, the condition described as ringing in the ears when no external sounds are present. Usually brought on by exposure to loud noise, the problem is especially significant in the military, with more than 34 percent of returning veterans from Iraq and Afghanistan suffering from the condition. For many sufferers, the ringing noise causes fatigue, depression, anxiety, and problems with memory and concentration.
Research has demonstrated that Neuromonics devices yield clinically significant reduction in tinnitus disturbance for more than 90 percent of suitable patients in a formal clinical trial setting. Using Neuromonics devices, study results show that patients experience a reduction in their tinnitus symptoms of 50 percent of more. In a study at the Hollywood, Fla., Veterans Administration Hospital, 96 percent of patients reported a reduction in their TRQ (Tinnitus Reaction Questionnaire), a self-report questionnaire that evaluates tinnitus distress, by 40 percent or more.
Neuromonics, Inc. (http://www.neuromonics.com)
Based in Westminster, Colo., Neuromonics, Inc., manufactures and distributes clinically proven medical devices to treat tinnitus. The patented and clinically proven Neuromonics Oasis™ provides long-term treatment and significant relief for those with severe tinnitus. The Haven, with the ability to program and individualize hearing profiles, is a management tool offering situational relief for tinnitus symptoms. The Sanctuary, also a management tool, works with pre-programmed profiles for on-demand relief.
With research and development beginning in the early 1990s, Neuromonics has helped thousands of tinnitus sufferers improve their quality of life and overcome the daily life challenges associated with tinnitus. Today, Neuromonics provides its devices to nearly 2,000 hearing professionals on four continents, through direct relationships and reseller partners. Neuromonics news includes segments on national media including “The Doctors” and CNN.
Aimee Bennett, Fagan Business Communications, http://www.neuromonics.com, +1 303-843-9840, [email protected]
Share this article